Cell-specific delivery of GJB2 restores auditory function in mouse models of DFNB1 deafness and mediates appropriate expression in NHP cochlea
簡介:
- 作者: Maryna V Ivanchenko, Kevin T A Booth, K Domenica Karavitaki, Larisa M Antonellis, M Aurel Nagy, Cole W Peters, Spencer Price, Yaqiao Li, Anton Lytvyn, Andrew Ward, Eric C Griffith, Sinisa Hrvatin, Michael E Greenberg, David P Corey
- 雜志: Nature Communications
- Doi: https://www.doi.org/10.1038/s41467-025-66110-2
- 出版日期: 2025/12/16
摘要
Mutations in the GJB2 gene cause DFNB1, the most common hereditary hearing loss. GJB2 is expressed by cochlear epithelial cells and fibrocytes, but not by sensory hair cells or neurons. Attempts to treat DFNB1 mouse models with gene therapy have not substantially restored function, as inappropriate expression in hair cells and neurons might compromise their electrical activity. Here, we use ATAC-seq to identify candidate gene regulatory elements (GREs) that can drive cell-type-specific expression of GJB2. HA-tagged GJB2, delivered to a conditional knockout mouse with AAV vectors carrying GREs, is expressed by the appropriate cells, prevents degeneration, and rescues hearing by only 10–20?dB. In a Gjb2 partial knockdown model, a vector lacking HA prevents degeneration and completely restores hearing. In cynomolgus monkey cochleas, human GJB2.HA delivered with similar vectors is located in the appropriate cell types and causes little or no compromise of hearing sensitivity. Together, these findings suggest that GRE-mediated expression of GJB2 can prevent hearing loss in DFNB1 patients.
關于派真
作為一家專注于AAV 技術十余年,深耕基因治療領域的CRO&CDMO,派真生物可提供從載體設計、構建到 AAV、慢病毒和 mRNA 服務的一站式解決方案。憑借深厚的技術實力、卓越的運營管理和高標準的服務交付,我們為全球客戶提供一站式CMC解決方案,包括從早期概念驗證、成藥性評估到IIT、IND及BLA的各個階段。
?
憑借我們獨立知識產權的π-alphaTM 293 細胞AAV高產技術平臺,我們能將AAV產量提高多至10倍,每批次產量可達1×101?vg,以滿足多樣化的商業化和臨床項目需求。此外,我們定制化的mRNA和脂質納米顆粒(LNP)產品及服務覆蓋藥物和疫苗開發的各個階段,從研發到符合GMP的生產,提供端到端的一站式解決方案。